The University of Osaka (JP)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
101
Publications
2289
Citations
50212
i10-index
918
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Nivolumab versus chemotherapy in patients with adv... | 2019 | 1176 |
Two FOXP3+CD4+ T cell subpopulations distinctly co... | 2016 | 853 |
Reprogramming of Mouse and Human Cells to Pluripot... | 2011 | 747 |
CD13 is a therapeutic target in human liver cancer... | 2010 | 602 |
Esophageal cancer practice guidelines 2017 edited ... | 2018 | 582 |
Nivolumab Combination Therapy in Advanced Esophage... | 2022 | 532 |
Esophageal cancer practice guidelines 2017 edited ... | 2018 | 522 |
Exosomal microRNA in serum is a novel biomarker of... | 2015 | 479 |
Guidelines for Diagnosis and Treatment of Carcinom... | 2014 | 454 |
Thoracic and cardiovascular surgery in Japan durin... | 2016 | 398 |
Yuichiro� Doki is a researcher with 2289 publications and 50212 citations. They are affiliated with The University of Osaka. Their research focuses on . With an h-index of 101, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Yuichiro� Doki and 250M+ other papers.
Citations per publication by year